[go: up one dir, main page]

DK13788D0 - Fremgangsmaade til fremstilling af et polypeptid - Google Patents

Fremgangsmaade til fremstilling af et polypeptid

Info

Publication number
DK13788D0
DK13788D0 DK013788A DK13788A DK13788D0 DK 13788 D0 DK13788 D0 DK 13788D0 DK 013788 A DK013788 A DK 013788A DK 13788 A DK13788 A DK 13788A DK 13788 D0 DK13788 D0 DK 13788D0
Authority
DK
Denmark
Prior art keywords
pct
polypeptide
secretion sequence
terminal secretion
preparing
Prior art date
Application number
DK013788A
Other languages
English (en)
Other versions
DK13788A (da
Inventor
Ian Barry Holland
Nigel Mackman
Jean-Marc Nicaud
Original Assignee
Ian Barry Holland
Nigel Mackman
Nicaud Jean Marc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ian Barry Holland, Nigel Mackman, Nicaud Jean Marc filed Critical Ian Barry Holland
Publication of DK13788D0 publication Critical patent/DK13788D0/da
Publication of DK13788A publication Critical patent/DK13788A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
    • C12N9/6481—Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK013788A 1986-05-15 1988-01-13 Fremgangsmaade til fremstilling af et polypeptid DK13788A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868611832A GB8611832D0 (en) 1986-05-15 1986-05-15 Polypeptide
PCT/GB1987/000331 WO1987006953A1 (en) 1986-05-15 1987-05-14 Process for the production of a polypeptide

Publications (2)

Publication Number Publication Date
DK13788D0 true DK13788D0 (da) 1988-01-13
DK13788A DK13788A (da) 1988-03-15

Family

ID=10597902

Family Applications (1)

Application Number Title Priority Date Filing Date
DK013788A DK13788A (da) 1986-05-15 1988-01-13 Fremgangsmaade til fremstilling af et polypeptid

Country Status (9)

Country Link
US (1) US5143830A (da)
EP (1) EP0267224B1 (da)
JP (1) JPS63503274A (da)
AT (1) ATE80660T1 (da)
AU (1) AU600949B2 (da)
DE (1) DE3781765T2 (da)
DK (1) DK13788A (da)
GB (2) GB8611832D0 (da)
WO (1) WO1987006953A1 (da)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
US5037743A (en) * 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US6210948B1 (en) 1992-06-09 2001-04-03 The University Of British Columbia Expression and secretion of heterologous polypeptides from caulobacter
US5914254A (en) * 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
US5563046A (en) * 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
US6214794B1 (en) 1994-12-02 2001-04-10 The Johns Hopkins University School Of Medicine Method of using hedgehog polypeptides to regulate neuronal cell growth
US6911528B1 (en) 1994-12-02 2005-06-28 The Johns Hopkins University School Of Medicine Hedgehog-derived polypeptides
US6057091A (en) * 1994-12-02 2000-05-02 The Johns Hopkins University School Of Medicine Method of identifying compounds affecting hedgehog cholesterol transfer
US6281332B1 (en) * 1994-12-02 2001-08-28 The Johns Hopkins University School Of Medicine Hedgehog-derived polypeptides
JPH1075774A (ja) * 1996-05-31 1998-03-24 Akzo Nobel Nv パスツレラ科の弱毒化ｒｔｘ産生細菌
KR100611063B1 (ko) 1996-10-16 2006-08-09 지모제넥틱스, 인코포레이티드 섬유아세포 성장인자 상동체
WO1998023763A1 (en) * 1996-11-29 1998-06-04 The General Hospital Corporation Heterologous antigens in live cell v. cholerae strains
CA2284733C (en) 1997-03-24 2010-10-26 Zymogenetics, Inc. Motilin homologs
CA2331199C (en) 1998-06-10 2012-10-23 Markus Sakari Kauppinen Isolated mannanases for use in treating cellulosic or synthetic fibers
EA201001190A1 (ru) 1998-09-23 2011-04-29 Займодженетикс, Инк. Выделенное антитело, специфически связанное с полипептидом, состоящее из последовательности аминокислотных остатков
ES2312223T3 (es) 1998-12-07 2009-02-16 Zymogenetics, Inc. Zvegf3 homologo de factor de crecimiento.
DK1642973T3 (da) 1999-01-07 2009-11-02 Zymogenetics Inc Terapeutisk anvendelser af BR43X2-oplöselige receptorer
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
CA2261186A1 (en) 1999-02-19 2000-08-19 University Of British Columbia Expression and secretion of heterologous polypeptides from freshwater caulobacter
BR0008772B1 (pt) 1999-03-09 2011-11-01 vetor de expressão, célula bacteriana ou fúngica cultivada, processos para expandir in vitro células hematopoiéticas e progenitores de células hematopoiéticas, e para detectar a presença de rna de ligando zalfa11 e de ligando zalfa 11 in vitro em uma amostra biológica.
US6664386B1 (en) 1999-04-08 2003-12-16 The Research Foundation Of State University Of New York System for efficient secretion of recombinant proteins
DE60034564T2 (de) 1999-07-07 2007-12-27 Zymogenetics, Inc., Seattle Menschlicher cytokinrezeptor
WO2001044289A2 (en) * 1999-12-17 2001-06-21 University Of Guelph Office Of The Vice President Of Research Modified leukotoxin gene and protein
ATE459716T1 (de) 1999-12-23 2010-03-15 Zymogenetics Inc Zytokin zcyt018
AU2001253127A1 (en) 2000-04-05 2001-10-23 Zymogenetics Inc. Soluble zalpha11 cytokine receptors
EP2258725A3 (en) 2000-06-26 2014-09-17 ZymoGenetics, L.L.C. Cytokine receptor zcytor17
US7863020B2 (en) 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
US7795002B2 (en) * 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
CA2413258C (en) 2000-06-30 2012-01-03 Zymogenetics, Inc. Interferon-like protein zcyto21
EP1736545A3 (en) 2000-08-08 2007-03-28 ZymoGenetics, Inc. Soluble zcytor 11 cytokine receptors
KR100447530B1 (ko) * 2001-08-14 2004-09-08 한국과학기술원 ＯｍｐＦ를 이용하여 목적 단백질을 대장균 세포외로분비생산하는 방법
AU2002347426B2 (en) 2001-10-15 2007-05-10 Engeneic Molecular Delivery Pty Ltd Intact minicells as vectors for DNA transfer and gene therapy in vitro and in vivo
EP2130919A1 (en) 2001-11-05 2009-12-09 ZymoGenetics, Inc. IL-21 antagonists
US7087418B2 (en) * 2001-12-19 2006-08-08 Bristol-Myers Squibb Company Pichia pastoris formate dehydrogenase and uses therefor
DE60333963D1 (de) 2002-01-18 2010-10-07 Zymogenetics Inc Zytokin Ligand zur Behandlung von Asthma und Atemwegsüberreaktivität
ATE547430T1 (de) 2002-01-18 2012-03-15 Zymogenetics Inc Multimere des cytokinrezeptors zcytor17
RU2004133765A (ru) 2002-04-19 2005-06-27 ЗАЙМОДЖЕНЕТИКС Инк. (US) Рецептор цитокина
EP1531850B1 (en) 2002-06-07 2012-02-22 ZymoGenetics, Inc. Use of IL-21 and monoclonal antibody for treating solid cancers
WO2004078965A1 (ja) * 2003-03-05 2004-09-16 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 大腸菌における異種蛋白質の製造方法
US20040241677A1 (en) * 2003-05-29 2004-12-02 Lin Jeffrey S Techniques for automated diagnosis of cell-borne anomalies with digital optical microscope
ES2296423B1 (es) * 2003-07-31 2009-03-16 Consejo Sup. Investig. Cientificas Construccion de adn para la produccion de proteinas de fusion dimericas y sus aplicaciones.
CA2534907C (en) 2003-08-07 2014-04-29 Zymogenetics, Inc. Homogeneous preparations of il-28 and il-29
EP2087905A2 (en) 2003-08-08 2009-08-12 Novo Nordisk A/S Interleukin-20 for treating and diagnosing conditions associated with neovascularisation
CN102516386A (zh) 2003-10-10 2012-06-27 诺沃挪第克公司 Il-21衍生物
EP2641611A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
PL1694361T3 (pl) 2003-12-09 2011-08-31 Engeneic Molecular Delivery Pty Ltd Ukierunkowane dostarczanie genów do niefagocytujących komórek ssaczych z zastosowaniem nienaruszonych minikomórek pochodzących od bakterii
US7381794B2 (en) 2004-03-08 2008-06-03 Zymogenetics, Inc. Dimeric fusion proteins and materials and methods for producing them
AU2005266892B2 (en) 2004-07-29 2011-03-03 Bristol-Myers Squibb Company Use of IL-28 and IL-29 to treat cancer and autoimmune disorders
EP1781784A2 (en) 2004-08-02 2007-05-09 BASF Plant Science GmbH Method for isolation of transcription termination sequences
EP2386640B1 (en) 2004-08-26 2015-01-28 EnGeneIC Molecular Delivery Pty Ltd Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
WO2006086396A2 (en) 2005-02-08 2006-08-17 Zymogenetics, Inc. Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
EP3683230A1 (en) 2005-05-12 2020-07-22 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
US7393667B2 (en) * 2005-05-31 2008-07-01 Bristol-Myers Squibb Company Stereoselective reduction process for the preparation of pyrrolotriazine compounds
AU2006278229B2 (en) * 2005-08-09 2011-10-27 Ares Trading S.A. Methods for treating B-cell malignancies using TACI-Ig fusion molecule
JP5118037B2 (ja) 2005-08-09 2013-01-16 ザイモジェネティクス， インコーポレイテッド Ｔａｃｉ融合分子を用いた異常細胞増殖の処置及び予防のための方法
UA98462C2 (ru) * 2006-05-15 2012-05-25 Арес Трейдинг С.А. Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig
CA2658058C (en) 2006-06-23 2016-08-23 Engeneic Molecular Delivery Pty Ltd. Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US8318664B2 (en) 2007-05-31 2012-11-27 Alize Pharma Sas Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity
CN101678084B (zh) * 2007-05-31 2015-01-21 阿利兹药物股份有限公司 未酰基化的生长素释放肽作为治疗代谢紊乱中的治疗剂
CA2971794C (en) 2007-10-04 2020-03-24 Zymogenetics, Inc. B7 family member zb7h6 and related compositions and methods
CA2706550C (en) 2007-11-21 2021-12-14 Roskilde Universitet Polypeptides comprising an ice-binding activity
EP2231702A1 (en) * 2007-12-21 2010-09-29 Ifxa A/s Protease inhibitor
NZ600205A (en) * 2008-01-25 2013-12-20 Univ Aarhus Selective exosite inhibition of papp-a activity against igfbp-4
ES2456296T3 (es) 2008-03-27 2014-04-21 Zymogenetics, Inc. Composiciones y procedimientos para inhibir PDGFR beta y VEGF-A
US8658766B2 (en) 2008-06-27 2014-02-25 Zymogenetics, Inc. Soluble hybrid Fcγ receptors and related methods
CA2733425A1 (en) 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
WO2011156356A1 (en) 2010-06-09 2011-12-15 Zymogenetics, Inc. Dimeric vstm3 fusion proteins and related compositions and methods
WO2012106281A2 (en) 2011-01-31 2012-08-09 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
EP2583975A1 (en) * 2011-10-21 2013-04-24 Heinrich-Heine-Universität Düsseldorf Agents and methods for the expression and secretion of peptides and proteins
CA3156904A1 (en) 2012-02-01 2013-08-08 Synthetic Genomics, Inc. Materials and methods for the synthesis of error-minimized nucleic acid molecules
US9862932B2 (en) 2012-07-24 2018-01-09 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
WO2014035474A1 (en) 2012-08-30 2014-03-06 The General Hospital Corporation Compositions and methods for treating cancer
JP6352920B2 (ja) 2012-09-04 2018-07-04 セレクティス 多重鎖キメラ抗原受容体およびその使用
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
WO2014175164A1 (ja) * 2013-04-25 2014-10-30 株式会社カネカ Ｆａｂ型抗体の分泌量を増大できるＦｄ鎖遺伝子又はＬ鎖遺伝子
PL3546572T3 (pl) 2013-05-13 2024-07-22 Cellectis Chimeryczny receptor antygenowy swoisty względem cd19 i jego zastosowania
WO2014202089A2 (en) 2013-06-18 2014-12-24 Roskilde Universitet Variants of anti-freeze polypeptides
US20160303174A1 (en) 2013-12-11 2016-10-20 The General Hospital Corporation Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors
CA2934436A1 (en) 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
ES2877606T3 (es) 2014-03-19 2021-11-17 Cellectis Método para la fabricación de células T CAR específicas de CD123 para inmunoterapia del cáncer
EP3137498A1 (en) 2014-05-02 2017-03-08 Cellectis Cs1 specific multi-chain chimeric antigen receptor
AU2015295349B2 (en) 2014-07-29 2020-09-24 Cellectis ROR1(NTRKR1)specific chimeric antigen receptors for cancer immunotherapy
WO2016016343A1 (en) 2014-07-31 2016-02-04 Cellectis Ror1 specific multi-chain chimeric antigen receptor
DK3189073T4 (da) 2014-09-04 2025-08-18 Cellectis Trofoblastglykoprotein (5t4, tpbg)-specifikke kimære antigenreceptorer til cancerimmunterapi
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
DK3250606T3 (da) 2015-01-26 2021-01-04 Cellectis ANTI-CLL1-specifikke enkeltkædede kimære antigenreceptorer (SCCARS) til cancerimmunterapi
ES2807591T3 (es) 2015-04-13 2021-02-23 Pfizer Receptores de antígeno quimérico dirigidos a antígeno de maduración de células B
EP3283529B1 (en) 2015-04-17 2023-06-07 The General Hospital Corporation Agents, systems and methods for treating cancer
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
AU2016263513A1 (en) 2015-05-20 2017-11-23 Cellectis Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy
KR102440820B1 (ko) 2015-09-08 2022-09-05 테리피온, 인크. ApoA-1 융합 폴리펩티드 및 관련 조성물 및 방법
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
MY192474A (en) 2016-01-21 2022-08-23 Pfizer Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
JP7213798B2 (ja) 2016-10-06 2023-01-27 エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド 核酸アジュバントを送達するための細菌ミニ細胞およびその使用方法
WO2018073394A1 (en) 2016-10-19 2018-04-26 Cellectis Cell death inducing chimeric antigen receptors
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018136163A2 (en) 2016-12-09 2018-07-26 Theripion, Inc. Tandem apoa-1 fusion polypeptides
BR112019020203A2 (pt) 2017-03-31 2020-06-02 Cellectis Sa Células imunes universais modificadas do receptor de anticorpos quiméricos anti-cd22
KR20190141206A (ko) 2017-04-19 2019-12-23 알로젠 테라퓨틱스 인코포레이티드 개선된 t 세포 조성물 및 방법
WO2018222935A1 (en) 2017-06-02 2018-12-06 Pfizer Inc. Chimeric antigen receptors targeting flt3
US12144825B2 (en) 2017-06-30 2024-11-19 Cellectis Cellular immunotherapy for repetitive administration
BR112020001180A2 (pt) 2017-07-20 2020-09-08 Aptevo Research And Development Llc proteínas de ligação a antígenos que se ligam a 5t4 e 4-1bb e composições e métodos relacionados
WO2019072824A1 (en) 2017-10-09 2019-04-18 Cellectis IMPROVED ANTI-CD123 CAR IN UNIVERSAL MODIFIED IMMUNE T LYMPHOCYTES
US11326156B2 (en) 2017-11-01 2022-05-10 Allogene Therapeutics, Inc. Modified caspase-9 polypeptides and methods of use thereof
JP7087107B2 (ja) 2017-12-20 2022-06-20 ハーバー・バイオメド・（シャンハイ）・カンパニー・リミテッド Ｃｔｌａ－４に結合する抗体およびその使用
US10150801B1 (en) 2017-12-27 2018-12-11 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
ES3039238T3 (en) 2017-12-27 2025-10-20 Imunami Laboratories Pte Ltd Recombinant polypeptides and methods of use thereof
PE20252242A1 (es) 2018-02-01 2025-09-15 Pfizer Receptores de antigeno quimericos dirigidos a cd70
WO2019152705A1 (en) 2018-02-01 2019-08-08 Pfizer Inc. Antibodies specific for cd70 and their uses
US12163169B2 (en) 2018-03-02 2024-12-10 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
WO2020007593A1 (en) 2018-07-02 2020-01-09 Cellectis Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml
WO2020099572A1 (en) 2018-11-14 2020-05-22 Fundación Pública Andaluza Progreso Y Salud Polynucleotide for safer and more effective immunotherapies
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
MX2022001882A (es) 2019-08-12 2022-05-30 Aptevo Res & Development Llc Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.
US10675332B1 (en) 2019-08-26 2020-06-09 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
WO2021040610A1 (en) 2019-08-26 2021-03-04 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
US20230167197A1 (en) 2020-03-18 2023-06-01 Memorial Sloan Kettering Cancer Center Anti-ceramide antibodies
WO2021185969A1 (en) 2020-03-18 2021-09-23 Numaferm Gmbh Variants of hlya and uses thereof
EP3882260A1 (en) * 2020-03-18 2021-09-22 NUMAFERM GmbH Fragments of hlya and uses thereof
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN116568317A (zh) 2020-06-22 2023-08-08 免疫实验室私人有限公司 用于癌症治疗的重组多肽和组合
AU2021312871A1 (en) 2020-07-21 2023-02-09 Allogene Therapeutics, Inc. Chimeric antigen receptors with enhanced signaling and activities and uses thereof
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
EP4215609A4 (en) 2020-09-21 2024-12-04 Fundación Pública Andaluza Progreso Y Salud POLYNUCLEOTIDE FOR PHYSIOLOGICAL EXPRESSION IN T CELLS
WO2022119976A1 (en) 2020-12-01 2022-06-09 Aptevo Research And Development Llc Heterodimeric psma and cd3-binding bispecific antibodies
MX2023007384A (es) 2020-12-21 2023-07-05 Allogene Therapeutics Inc Car con puerta cd45 activado por proteasa.
MX2023008809A (es) 2021-01-29 2023-08-04 Allogene Therapeutics Inc ATENUACIÓN O INACTIVACIÓN DE UNO O MÁS DE TAP2, NLRC5, ß2M, TRAC, RFX5, RFXAP Y RFXANK PARA MITIGAR EL RECONOCIMIENTO DE CÉLULAS T DE PRODUCTOS CELULARES ALOGÉNICOS.
EP4294916A2 (en) 2021-02-19 2023-12-27 Theripion, Inc. Dnase fusion polypeptides and related compositions and methods
EP4301772A1 (en) 2021-03-04 2024-01-10 Allogene Therapeutics, Inc. Fasl expression and fasr gene knockout to protect therapeutic cells from allogeneic rejection and activation-induced cell death
US20240228553A1 (en) 2021-03-18 2024-07-11 Numaferm Gmbh Fusion proteins comprising gg repeat sequences
BR112023026249A2 (pt) 2021-06-15 2024-03-05 Allogene Therapeutics Inc Direcionamento seletivo de células alorreativas cd70+ do hospedeiro para prolongar a persistência de células t car alogênicas
WO2023192895A1 (en) 2022-03-29 2023-10-05 Allogene Therapeutics Inc. Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals
CN119654406A (zh) 2022-07-29 2025-03-18 艾洛基治疗公司 具有降低的基因表达以减轻免疫细胞识别的经工程化的细胞
EP4339202A1 (en) 2022-09-16 2024-03-20 NUMAFERM GmbH Fusion proteins comprising gg repeat sequences ii
KR20250133692A (ko) 2023-01-06 2025-09-08 압테보 리서치 앤드 디벨롭먼트 엘엘씨 이중특이성 pd-l1 및 cd40 결합 분자 그리고 이의 용도
WO2024259220A1 (en) 2023-06-15 2024-12-19 Theripion, Inc. Pon3 and evolved pon1 fusion polypeptides
WO2025096560A1 (en) 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Engineered cells

Also Published As

Publication number Publication date
DE3781765T2 (de) 1993-04-22
GB8800141D0 (en) 1988-03-02
DK13788A (da) 1988-03-15
DE3781765D1 (de) 1992-10-22
GB8611832D0 (en) 1986-06-25
GB2197324B (en) 1990-04-11
EP0267224A1 (en) 1988-05-18
AU600949B2 (en) 1990-08-30
EP0267224B1 (en) 1992-09-16
US5143830A (en) 1992-09-01
ATE80660T1 (de) 1992-10-15
WO1987006953A1 (en) 1987-11-19
AU7392387A (en) 1987-12-01
GB2197324A (da) 1988-05-18
JPS63503274A (ja) 1988-12-02

Similar Documents

Publication Publication Date Title
DK13788D0 (da) Fremgangsmaade til fremstilling af et polypeptid
DK0423302T3 (da) Anvendelse af hidtil ukendte DNA-fragmenter som kodende sekvens for et signalpeptid til sekretion af modne proteiner i rekombinant gær, ekspressionskassetter, transformeret gær og tilsvarende fremgangsmåde til fremstilling af proteiner
DE69128285D1 (de) Expression rekombinanter polypeptide mit verbesserter möglichkeit zur reinigung
DK219087A (da) Vektorsystem til brug ved transformation af trichoderma, transformerede trichodermastammer og fremgangsmaade til fremstilling af proteiner heri
EP0722461A4 (en) EXPRESSION OF FUSION POLYPEPTIDES TRANSPORTED OUT OF CYTOPLASM WITHOUT HEAD SEQUENCE
DK161152C (da) Polypeptid med egenskaber som human beta-nervevaekstfaktor og fremgangsmaade til fremstilling deraf, dna-isolat omfattende en sekvens som koder for polypeptidet, replicerbar udtrykkelsesvektor for dna-sekvensen, rekombinant vaertscelle transformeret med vektoren, farmaceutisk praeparat indeholdende polypeptidet og fremg. der omfatter anvendelsen af polypeptidet til fremst. af et farmaceutisk praeparat
HU9203449D0 (en) Varied cd44 surfacial proteins, dna sequences coding them, antibodies acting against these proteins as well as application of all these things in diagnostics and therapy
FI102075B1 (fi) Menetelmä valmistaa glykosyloitu tai glykosyloimaton polypeptidi, rekombinanttinukleiinihappo ja vektorit
DK645887D0 (da) Gamma-hesteinterferon, fremgangsmaade til fremstilling af, samt anvendelse af en saadan forbindelse
ES8802394A1 (es) Un procedimiento para preparar una proteina de fusion derivada de la secuencia de aminoacidos de la preprorrelaxina humana.
DE69233463D1 (de) Expression und reinigung von kloniertem humanen alpha-fetoprotein
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
NO930428L (no) Proteinstrukturen til plantetoksingelonin
DE3877035D1 (de) Gentechnologisches verfahren zur herstellung von polypeptiden.
DK35888A (da) Fremgangsmaade til fremstilling af rekombinant polypeptider
DE3873273D1 (de) Verfahren zur selektiven spaltung von fusionsproteinen.

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment